Optimal management of obesity-associated inflammatory arthritis requires coordinated implementation of lifestyle modifications (including structured dietary intervention and progressive physical activity programs) [22], conventional disease-modifying antirheumatic drugs (DMARDs) and/or biological therapies targeting specific inflammatory pathways, and emerging metabolic interventions such as incretin analogs. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.